



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/060,754	01/30/2002	Jeffry B. Skiba	125827-1000	8210
62486	7590	09/01/2006	EXAMINER	
SHERRY SCHUMM c/o INTELLEVATE, LLC P.O. BOX 52050 MINNEAPOLIS, MN 55402			ANDERSON, CATHARINE L	
			ART UNIT	PAPER NUMBER
			3761	

DATE MAILED: 09/01/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 10/060,754	Applicant(s) SKIBA ET AL.	
	Examiner C. Lynne Anderson	Art Unit 3761	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 26 June 2006.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-6,8,10,11,15,17-22 and 24-31 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-6,8,10,11,15,17-22 and 24-31 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Response to Arguments

Applicant's arguments filed 26 June 2006 have been fully considered but they are not persuasive.

In response to the applicant's argument that Kang fails to disclose elongated conduits, it is noted that the conduit 11 shown in figure 3 of Kang that leads from the atomizer 20 to the eye pieces of the mask 10 has a length, and is therefore elongated.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-6, 10-11, 15, 17, 19-22, and 25-31 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kang (5,807,357) in view of Hewitt et al. (5,216,759).

Kang discloses all aspects of the claimed invention with the exception of the conduits being flexible. Kang discloses an apparatus for delivering medicine to tissues, as shown in figure 2, comprising a mask 10 to be worn around the eyes, the mask 10 comprising fog outlets (shown as holes in figure 3, but not numbered). An atomizer 20 atomizes medicine 90 into a fog to be discharged from the fog outlets. The atomizer 20 is connected to the fog outlets by elongated conduit 11, as shown in figure 3.

Hewitt discloses goggles of a similar construction to the mask of Kang, and teaches constructing the mask using a flexible material in order to allow the mask to

Art Unit: 3761

conform to the wearer, as disclosed in column 3, lines 47-52. A mask that conforms to the face of the wearer provides a secure fit, which would ensure the fog discharged into the mask of Kang would not escape the mask, and therefore the mask of Kang would be more effective in delivering the fog to the eyes of the wearer. If the mask of Kang is constructed from a flexible material, the conduits, which comprise part of the mask, would also be flexible.

It would therefore be obvious to one of ordinary skill in the art at the time of invention to construct the mask of Kang out of a flexible material, as taught by Hewitt, to allow the mask to conform to the wearer and provide a secure fit.

With respect to claim 2, the atomizer 20 comprises an ultrasonic atomizer, as disclosed in column 2, lines 29-32.

With respect to claim 3, the atomizer 20 comprises a nozzle 11, as shown in figure 3.

With respect to claim 4, the atomizer 20 is a nebulizer, as disclosed in column 1, line 54.

With respect to claim 5, Kang discloses all aspects of the claimed invention with the exception of the atomizer being a stirrer. Stirrers are well-known in the art as being suitable atomizers comparable to nebulizers. It would therefore be obvious to one of ordinary skill in the art at the time of invention to make the apparatus of Kang with a stirrer.

With respect to claim 6, the atomizer 20 comprises a medication chamber 71, as shown in figure 2.

With respect to claims 10-11 and 26-27, Kang discloses all aspects of the claimed invention with the exception of the propellant source comprising a compressed gas canister or a pump. Kang discloses the propellant source is a fan, as described in column 2, lines 33-35. It is well-known in the art that a compressed gas canister or pump perform a comparable function to a fan, and it would therefore be obvious to one of ordinary skill in the art at the time of invention to construct the apparatus of Kang with a compressed gas canister or a pump.

With respect to claim 15, the apparatus comprises a mask 10 having a transparent face mask 12 to be worn around the eyes, fog outlets (shown as holes in figure 3, but not numbered), an atomizer 20 to atomize medicine 90 into a fog, a medication chamber 71, a power supply 40, a propellant source 30, and a conduit 11.

With respect to claim 17, the power supply 40 comprises a battery, as disclosed in column 1, line 60.

With respect to claims 19 and 20, the method of administering medications to the eyes by nebulizing a medication to form a fog and contacting the fog with the eyes is disclosed in column 2, lines 27-36.

With respect to claim 21, the apparatus comprises a device 10 comprising fog outlets (shown as holes in figure 3, but not numbered), and an atomizer 20 in fluid communication with the fog outlets.

With respect to claim 22, the atomizer 20 is a nebulizer, as disclosed in column 1, line 54.

Art Unit: 3761

With respect to claim 25, a propellant source 30 is in fluid communication with the atomizer 20.

With respect to claim 28, a power supply 40 is connected to the atomizer 20.

With respect to claim 29, the power supply 40 comprises batteries, as disclosed in column 1, line 60.

With respect to claims 30 and 31, Kang discloses a method of providing the mask described above and atomizing fluid into a fog, as disclosed in column 2, lines 27-36.

Claims 8, 18, and 24 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kang (5,807,357) in view of Hewitt et al. (5,216,759) as applied to claims 1, 15, and 21 above, and further in view of Dykstra et al. (5,935,982).

Kang, as modified by Hewitt, discloses all aspects of the claimed invention but remains silent as to the size of the liquid droplets of the fog. Dykstra discloses administering a medicine to the eyes, the medicine being in the form of liquid droplets having a size of less than 5 microns, as described in column 12, lines 13-15 and 36-37. It would therefore be obvious to one of ordinary skill in the art at the time of invention to make the droplets of Kang less than 5 microns, since Kang teaches less than 5 microns as a suitable size for medicine being delivered to the eyes.

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

Art Unit: 3761

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to C. Lynne Anderson whose telephone number is (571) 272-4932. The examiner can normally be reached on Monday through Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Tanya Zalukaeva can be reached on (571) 272-1115. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 3761

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

UA

cla

August 28, 2006

TATYANA ZALUKAEVA
SUPERVISORY PRIMARY EXAMINER

A handwritten signature in black ink, appearing to read 'T. Zalukaeva', with a long horizontal flourish extending to the right.